Skip to Content

Prilocaine Hydrochloride

Pronunciation: PRIL-oh-kane HYE-droe-KLOR-ide
Class: Local anesthetic

Trade Names

Citanest Forte
- Injection, solution 4%

Citanest Plain
- Injection, solution 4%


Stabilizes the neuronal membrane by inhibiting the ionic fluxes needed for the initiation and conduction of impulses, thereby affecting local anesthetic action.

Slideshow: Knowledge Center: Rheumatoid Arthritis



Metabolized by both the liver and kidney.


Excreted by the kidney.


Less than 2 min when used for infiltration injection in dental patients. When used for inferior alveolar nerve block, the onset averages less than 3 min.


Average duration of soft tissue anesthesia is approximately 2 h when used for infiltration injection in dental patients. Citanest Plain provides a duration of complete palpal anesthesia for procedures lasting 20 min. When used for inferior alveolar nerve block, the duration of soft tissue anesthesia with Citanest Plain and Citanest Forte is 2.5 and 3 h, respectively.

Special Populations

Renal Function Impairment

Pharmacokinetics may be altered.

Hepatic Function Impairment

Pharmacokinetics may be altered.

Indications and Usage

Production of local anesthesia in dentistry by nerve block or infiltration techniques.


Hypersensitivity to amide-type local anesthetics; patients with congenital or idiopathic methemoglobinemia.

Dosage and Administration


Infiltration For most routine procedures, initial doses of 1 to 2 mL will provide adequate infiltration or major nerve block anesthesia. Maximum recommended dose is 8 mg/kg (4 mg/lb) in patients weighing less than 70 kg (150 lb) and 600 mg in patients weighing 70 kg (150 lb) or more.

Children younger than 10 yr of age

Infiltration Seldom necessary to administer doses greater than 40 mg for a procedure involving a single tooth.


Store at 77°F. Protect from light.

Drug Interactions

Drugs associated with methemoglobinemia (eg, acetaminophen, benzocaine, chloroquine, dapsone, nitrates, nitrofurantoin, nitroglycerine, nitroprusside, phenobarbital, phenytoin, primaquine, quinine, sulfonamides)

Risk of methemoglobinemia may be increased.

Ergot derivatives (eg, ergotamine)

Severe, persistent hypertension or cerebrovascular accidents may occur.

MAOIs (eg, phenelzine), phenothiazines (eg, chlorpromazine), tricyclic antidepressants (amitriptyline)

Severe, prolonged hypertension or hypotension may occur. If possible, avoid coadministration.

Laboratory Test Interactions

IM injection may increase CPK levels.

Adverse Reactions


Bradycardia, cardiac arrest, CV collapse, hypotension, serious CV catastrophe, vasovagal reaction.


Apprehension; cerebral hypoxia; confusion; convulsion; depression; dizziness; drowsiness; euphoria; excitation; faintness; light-headedness; nervousness; persistent neurologic deficit; sensations of cold, heat, or numbness; seizures; tremors; twitching; unconsciousness.


Blurred or double vision, tinnitus.


Swelling and persistent paresthesia of the lips and oral tissue, vomiting.


Allergic reactions characterized by anaphylactic reactions, cutaneous lesions, edema, or urticaria.


Respiratory arrest or depression.


Feeling of tightness, sweating.



Monitor CV and respiratory vital signs and the state of consciousness.


Category B.




Dosage should be based on age, weight, and physical condition.

Hepatic Function

Use with caution.

Special Risk Patients

Administer reduced doses in debilitated elderly patients, acutely ill patients, and children. Use with caution in patients with impaired CV function, heart block or severe shock.

Sulfite Sensitivity

Prilocaine injection contains a sulfite that may cause allergic-type reactions including anaphylactic symptoms and life-threatening or less severe asthmatic episodes in susceptible individuals.


May occur.

Repeated administration

Increases in blood levels may occur.

Use in head and neck area

May cause adverse reactions similar to systemic toxicity.



Cardiovascular arrest, cardiovascular depression, and convulsions can lead to hypoxia, acidosis, bradycardia, arrhythmias, and cardiac arrest; respiratory depression.

Patient Information

  • Caution patients about the possibility of temporary loss of sensation and muscle function.
  • Caution patients to avoid inadvertent trauma to the cheek mucosa, lips, soft palate, or tongue.
  • Advise patients to consult their health care provider if anesthesia persists or a rash develops.

Copyright © 2009 Wolters Kluwer Health.